AHMEDABAD: A pharma major based in Ahmedabad on Tuesday launched a
patented research formulation
of Thymoquinone that is reported to boost immunity and give
greater success
in fighting infections.
The formulation has been launched under the name Thymotas by
Intas Pharmaceuticals Limited
.
“It has been tested clinically as a significant add-on to the standard treatment of
Covid-19
,” Intas said. Thymoquinone is the active biological component of Nigella sativa, (popularly known as kalonji, black cumin and kali jeeri).
“Various scientific publications prove Thymoquinone’s multiple pharmacologically beneficial properties,” the company said.
According to Intas, the formulation has been developed as a stable, standardized and ready-to-use tablet for the first time in the world.
“Thymotas 12.5mg is very successful in building immunity and combating infections effectively,” said Dr Alok Chaturvedi, senior vice-president and head of medical affairs, Intas.
The formulation fights infections through multimodal actions such as anti-viral, anti-bacterial, anti-inflammatory, immuno-modulatory and antioxidant properties.
“Manufactured at a WHO-GMP certified plant, Thymotas is an immunity booster and prophylaxis. One tablet of 12.5mg is recommended daily after meals or as directed by the physician,” the company said. The research and development team at Intas has also developed a Covid-19 specific hyperimmune globulin as treatment for patients suffering from moderate to severe Covid-19 infection.
Start a Conversation
Post comment